TY - JOUR
T1 - Defining and managing COVID-19-associated pulmonary aspergillosis
T2 - the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
AU - the Medical Mycology Society of Nigeria
AU - the Medical Mycology Society of China Medicine Education Association
AU - Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology
AU - Association of Medical Microbiology
AU - Infectious Disease Canada
AU - European Confederation of Medical Mycology
AU - the International Society for Human Animal Mycology
AU - the Asia Fungal Working Group
AU - the INFOCUS LATAM/ISHAM Working Group
AU - the ISHAM Pan Africa Mycology Working Group
AU - the European Society for Clinical Microbiology
AU - Infectious Diseases Fungal Infection Study Group
AU - the ESCMID Study Group for Infections in Critically Ill Patients
AU - the Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy
AU - Koehler, Philipp
AU - Bassetti, Matteo
AU - Chakrabarti, Arunaloke
AU - Chen, Sharon C.A.
AU - Colombo, Arnaldo Lopes
AU - Hoenigl, Martin
AU - Klimko, Nikolay
AU - Lass-Flörl, Cornelia
AU - Oladele, Rita O.
AU - Vinh, Donald C.
AU - Zhu, Li Ping
AU - Böll, Boris
AU - Brüggemann, Roger
AU - Gangneux, Jean Pierre
AU - Perfect, John R.
AU - Patterson, Thomas F.
AU - Persigehl, Thorsten
AU - Meis, Jacques F.
AU - Ostrosky-Zeichner, Luis
AU - White, P. Lewis
AU - Verweij, Paul E.
AU - Cornely, Oliver A.
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/6
Y1 - 2021/6
N2 - Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
AB - Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
UR - https://www.scopus.com/pages/publications/85099207213
U2 - 10.1016/S1473-3099(20)30847-1
DO - 10.1016/S1473-3099(20)30847-1
M3 - Review article
C2 - 33333012
AN - SCOPUS:85099207213
SN - 1473-3099
VL - 21
SP - e149-e162
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 6
ER -